PMID- 29599348
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR - 20180412
IS - 1791-7530 (Electronic)
IS - 0250-7005 (Linking)
VI - 38
IP - 4
DP - 2018 Apr
TI - Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small
Cell Lung Cancer.
PG - 2261-2269
AB - BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer
(NSCLC) compared to men might be explained by sex hormone-related mechanisms. We
investigated whether this observation could be explained by the expression of
estrogen receptor-alpha (ER-alpha) in tumor tissue. MATERIALS AND METHODS:
Archived, formalin fixed, paraffin embedded tumor tissue samples were
retrospectively analyzed for nuclear expression of ER-alpha with
immunohistochemistry. RESULTS: Biopsies from 222 patients were analyzed.
Twenty-three percent were ER-alpha positive. Fifty-four percent of the patients
were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%)
patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine
and carboplatin. Females with ER-alpha positive tumors who received PC had a
substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003).
CONCLUSION: ER-alpha is an independent prognostic factor in advanced NSCLC and
might also be a predictive factor for response to pemetrexed/carboplatin in
women.
CI - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J.
Delinasios), All rights reserved.
FAU - Lund-Iversen, Marius
AU - Lund-Iversen M
AD - Department of Pathology, Oslo University Hospital, Oslo, Norway
[email protected]
AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Scott, Helge
AU - Scott H
AD - Department of Pathology, Oslo University Hospital, Oslo, Norway.
AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Strom, Erik H
AU - Strom EH
AD - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Theiss, Noah
AU - Theiss N
AD - Ventana Medical Systems, Tucson, AZ, U.S.A.
FAU - Brustugun, Odd Terje
AU - Brustugun OT
AD - Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen,
Norway.
FAU - Gronberg, Bjorn H
AU - Gronberg BH
AD - Department of Clinical and Molecular Medicine, NTNU, Norwegian University of
Science and Technology, Trondheim, Norway.
AD - The Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim,
Norway.
LA - eng
PT - Clinical Trial, Phase III
PT - Journal Article
PT - Multicenter Study
PT - Randomized Controlled Trial
PL - Greece
TA - Anticancer Res
JT - Anticancer research
JID - 8102988
RN - 0 (Estrogen Receptor alpha)
RN - 0 (estrogen receptor alpha, human)
RN - 04Q9AIZ7NO (Pemetrexed)
RN - 0W860991D6 (Deoxycytidine)
RN - B76N6SBZ8R (gemcitabine)
RN - BG3F62OND5 (Carboplatin)
SB - IM
MH - Adult
MH - Aged
MH - Aged, 80 and over
MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH - Carboplatin/administration & dosage
MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/mortality/pathology
MH - Deoxycytidine/administration & dosage/analogs & derivatives
MH - Disease Progression
MH - Estrogen Receptor alpha/*metabolism
MH - Female
MH - Humans
MH - Immunohistochemistry
MH - Lung Neoplasms/drug therapy/*metabolism/mortality/pathology
MH - Male
MH - Middle Aged
MH - Pemetrexed/administration & dosage
MH - Retrospective Studies
OTO - NOTNLM
OT - *Prognostic factor
OT - *estrogen receptor
OT - *first-line chemotherapy
OT - *gender difference
OT - *immunohistochemistry
OT - *palliative chemotherapy
OT - *sex hormones
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2018/03/02 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2261 [pii]
AID - 10.21873/anticanres.12470 [doi]
PST - ppublish
SO - Anticancer Res. 2018 Apr;38(4):2261-2269. doi: 10.21873/anticanres.12470.